| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
, Interleukin 1ß, Interleukin 6,
-Interferon, and Soluble Interleukin 2 Receptor (Mr 55,000 Protein)1
Departments of Tumor Biology [J. L., W. G. L., E. A. G.] and Neurosurgery [R. P. M., M. S., J. B. B.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
Interleukin 2 (IL-2) is a potent immunostimulant that causes the release of secondary cytokines and the production of lymphokine-activated killer cells. We investigated the cellular and cytokine responses to injection of recombinant human IL-2 into the human cerebrospinal fluid of 11 patients with metastatic tumors involving the spinal or cerebral leptomeninges. After initial intraventricular IL-2 administration (1.25 x 105 to 2 x 106 Cetus units/injection), cerebrospinal fluid samples were collected at intervals from 0 to 24 h. Enzyme-linked immunosorbent assay results indicated that IL-2 levels gradually decreased during the first 24 h, with an average t
between 4 and 8 h. Induction of tumor necrosis factor
, interleukin 1ß, interleukin 6,
-interferon, and interleukin 2 receptor (p55) was also assessed by enzyme-linked immunosorbent assay. Tumor necrosis factor
and interleukin 6 levels peaked at 2 to 4 h and 4 to 6 h, with concentrations between 71 to 1,714 pg/ml and 942 to 10,500 pg/ml, respectively. Interleukin 1ß,
-interferon, and soluble IL-2 receptor peaked later, during 6 to 12 h; the levels achieved were 234 pg/ml, 25 NIH units/ml, and 207 units/ml, respectively. All cytokine concentrations returned to near baseline between 12 and 24 h; however, the soluble IL-2 receptor levels remained elevated. Additional observations included a rapid influx of neutrophilic leukocytes, followed by a prolonged presence of lymphocytes. These data indicate a broad and complex potential of the immune response in the central nervous system, as well as further define the cytokine cascade in response to IL-2 alone.
1 The work was supported in part by a gift from the Dunn Foundation, Houston, TX. J. L. was supported by Grant 482/1-1 from the Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany.
2 To whom requests for reprints should be addressed, at Department of Tumor Biology, Box 79, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030.
Received 9/ 3/91. Accepted 12/ 5/91.
This article has been cited by other articles:
![]() |
G. Chen, W. L. Castro, H.-H. Chow, and S. Reichlin Clearance of 125I-Labeled Interleukin-6 from Brain into Blood Following Intracerebroventricular Injection in Rats Endocrinology, November 1, 1997; 138(11): 4830 - 4836. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |